The Effect and Molecular Mechanisms of SB239063 on Regulating Aβ Generation in APPswe/PS1dE9 Mice

Qi YAN,Ying DU,Chao ZHAO,Zhuo ZHANG,Ai-li YANG,Jian-ting MIAO,Zhu-yi LI
DOI: https://doi.org/10.13241/j.cnki.pmb.2017.10.007
2017-01-01
Abstract:Objective:To investigate the efficacy and molecular mechanisms of SB239063 on cognitive deficits and Aβ generation in APPswe/PS1dE9 mice.Methods:Six-month-old male APPswe/PS1dE9 mice and their wild-type littermates were randomized into SB239063-treatedgroups and control groups respectively.The treated groups received SB239063 (dissolved in 3% DMSO at a dose of 15mg/kg) once per day by intraperitoneal injection,whereas the control groups received an equal volume of 3% DMSO once per day by intraperitoneal injection.Six weeks after the treatments,the spatial learning and memory ability of all mice were evaluated by the Morris water maze test,the levels of soluble Aβ were detected with enzyme-linked immunosorbent assay (ELISA) kits,the expression of crucial enzymes in the production of Aβ were tested with western blot method.Results:Compared with the vehicle-treated APPswe/PS1dE9 mice,the escape latency in reaching the hidden-platform were significantly decreased (P<0.01),while the percentage of time spend in the target quadrant (P<0.01) and the frequency of crossing the platform (P<0.01) were potently increased in SB239063-treated APPswe/PS1dE9 mice (P<0.01).Meanwhile,the levels of soluble Aβ1-42 (P<0.05),Aβ1-40 (P<0.05) and Aβ oligomers (P<0.01) were dramatically decreased in SB239063-treated APPswe/PS1dE9 mice versus the control group.In addition,the expression of p-p38MAPK,BACE1 and PS1 in APPswe/PS1dE9 mice were markedly reduced by SB239063 treatment (P<0.01).Conclusion:SB239063 can reverse cognitive impairments and Aβ toxicity by decreasing the expression of BACE1 and PS1 which may result from inhibition ofp-p38MAPK.Our findings provide that SB239063 may be a promising therapeutic strategy for the treatment of AD.
What problem does this paper attempt to address?